Catalent, Inc. (CTLT)
| Market Cap | 20.41B |
| Revenue (ttm) | 3.76B |
| Net Income (ttm) | 496.80M |
| Shares Out | 170.34M |
| EPS (ttm) | 2.95 |
| PE Ratio | 40.57 |
| Forward PE | 36.36 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $119.81 |
| Previous Close | $119.32 |
| Change ($) | 0.49 |
| Change (%) | 0.41% |
| Day's Open | 119.22 |
| Day's Range | 119.04 - 121.11 |
| Day's Volume | 920,123 |
| 52-Week Range | 79.65 - 127.68 |
Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities. The plant is curre...
Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.
If production setbacks can be avoided, gains should be in sight.
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.
Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc's (NYSE: EBS) Baltimore plant to a factory owned ...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to bolster its E.U. hub. Catalent has acquired Prome...
Catalent (CTLT) delivered earnings and revenue surprises of 7.90% and 5.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Catalent (NYSE:CTLT) decreased 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 64.00% over the past year to $0.82, which beat the es...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell ...
Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.
CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Catalent, Inc. (NYSE: CTLT), the ...
Catalent to double output of Moderna vaccine: Report
The U.S. coronavirus vaccine supply could be getting a new boost. According to the Wall Street Journal, contract manufacturer Catalent plans to nearly double its output of the Moderna vaccine, with the ...
Catalent Inc (NYSE: CTLT) is reportedly expanding its U.S. production of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine to ensure the U.S. has ample supply as it ramps up vaccinations. Catalent helps Mod...
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).
J&J COVID-19 Vaccine To Get Supply Boost As Manufacturing Partner Catalent Secures Key FDA Clearance
Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine is expected to get a significant supply boost after manufacturing partner Catalent Inc (NYSE: CTLT) secured a key U.S. regulator clearance, Bloomberg New...
TORONTO--(BUSINESS WIRE)--Cybin signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)
Despite occasional pullbacks in share price, these growth stocks are expected to continue to create shareholder value during the year. The post 7 Growth Stocks With Compelling Stories appeared first on ...
Catalent is scaling up manufacturing capacity for Johnson & Johnson's COVID-19 vaccine at its Italian plant, addressing some concerns over the drugmaker's ability to meet vaccine supply targets in the E...
Catalent Inc plans to expand its COVID-19 vaccine production in Europe that will enable it to make more doses of Johnson & Johnson's shot, the Wall Street Journal reported https://www.wsj.com/articles/c...
Catalent (CTLT) has been struggling lately, but the selling pressure may be coming to an end soon
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
USNA vs. CTLT: Which Stock Is the Better Value Option?
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, c...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, c...
Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Catalent, Inc. (CTLT) CEO John Chiminski on Q2 2021 Results - Earnings Call Transcript
Catalent (CTLT) delivered earnings and revenue surprises of 12.50% and 1.66%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Catalent (NYSE:CTLT) moved higher by 1.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 40.00% year over year to $0.63, which beat t...
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell ...
Catalent is forming a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Feb. 3. The post Earnings Season Preview: Catalent Near Buy Zone With EPS Due a...
Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene ...
Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.
Does Catalent (CTLT) have what it takes to be a top stock pick for momentum investors? Let's find out.
On Friday, Catalent got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Catalent Joins Rank Of Stocks With 95-Plus Composite Rating appeared first on Investor's Business Daily.
About CTLT
Catalent, Inc., together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplem... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jul 31, 2014 |
| Stock Exchange NYSE | Ticker Symbol CTLT |
Financial Performance
In 2020, Catalent's revenue was $3.09 billion, an increase of 22.89% compared to the previous year's $2.52 billion. Earnings were $220.70 million, an increase of 60.63%.
Analyst Forecasts
According to 12 analysts, the average rating for Catalent stock is "Strong Buy." The 12-month stock price forecast is 135.20, which is an increase of 12.85% from the latest price.